Minnesota Multidisciplinary Vasculitis Program

The Minnesota Multidisciplinary Vasculitis Program (M2VP) enrolls the 200th adult patient and 1st pediatric patient into the registry!

October 2021

m2vp-group-img

Front Row L to R: S. Thaker, S. Reule, M. Rheault, H. Boyer, C. Fanola, D. Pearson, H. Muster
Back Row L to R: P. Nachman, S. Rajala, L. Ghazi, M. Beard, P. Fazeli, K. Woerner, D. Mueller, M. Pritzker, P. Ardnt
 

Mission

To provide patients with systemic inflammatory disease or vasculitis with cutting-edge, individualized, comprehensive and integrated multidisciplinary care and access to Phase 2 clinical trials in ANCA Vasculitis and Systemic Lupus Erythematosus.  

Covered Diseases

  • Systemic vasculitis:
    • Small Vessel Vasculitis (ANCA-vasculitis, Anti-GBM disease, IgA Vasculitis)
    • Medium Vessel vasculitis 
    • Large Vessel vasculitis
  • Systemic Lupus Erythematosus

Goals

  • Provide patients with complex systemic diseases with multidisciplinary care which is organized, streamlined and efficient.
  • Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
  • Provide patients with access to cutting-edge clinical trials.
  • Facilitate translational research.
  • Provide a venue for health care providers training in the care of patients with complex systemic diseases.

Multidisciplinary Team

Cardiology

Dermatology

Nephrology

Otolaryngology (ENT)

Pulmonary

Rheumatology

Clinical & Translational Research Team

  • Tina Weiss, RN, BSN, PHN, Vasculitis & Lupus Program Nurse Navigator
  • Amy Hanson, CCRC, Clinical Research Coordinator, Pediatrics
  • Anael Kuperwajs Cohen, CCRC, Clinical Research Coordinator, Pediatrics
  • Scott Rajala, CCRP, Clinical Research Coordinator

Ongoing Clinical Trials

Expand all

ANCA Vasculitis

New Study Starting Soon!

Anti-GBM

A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)

Principal Investigator
Patrick Nachman, MD

Co-Investigators
Andrew Johnson, MD
Nattawat Klomjit, MD
Sahar Koubar, MBBS
Aahd Kubbara, MD
Katie Pendleton, MD
Sami Safadi, MD

Study Coordinator
Nicolas Rauwolf | 
rauwo004@umn.edu

CLINICAL TRIAL

Systemic Lupus Erythematosus (SLE)

A Phase 1 Study of FT819 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Principal Investigator
Parastoo Fazeli, MD

Co-Investigators
Jerry Molitor, MD, PhD
Patrick H. Nachman, MD
Marta Michalska Smith, MD

Study Coordinator:
Michelle Snyder, RN | 
snyde003@umn.edu

CLINICAL TRIAL


A Phase 1/2, Open-label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Systemic Lupus Erythematosus

Principal Investigator
Patrick H. Nachman, MD

Co-Investigators
Parastoo Fazeli, MD
Marie Hu, MD
Nattawat Klomjit, MD 

Study Coordinator:
Victoria Quinones, RN | 
quino072@umn.edu

CLINICAL TRIAL